Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Parker, a model of physician advocacy

Dr. Parker’s journey began with four years of dedicated service in the U.S. Marine Corps, where he earned accolades such as the Meritorious Unit Citation and Good Conduct Medal. His exceptional dedication led to acceptance into the U.S. Air Force Officer Training School and a subsequent role as a Minuteman II ICBM Commander within U.S. Space Command, earning further recognition, including the Presidential Unit Citation, National Defense Service Medal, and the Air Force Achievement Medal. Transitioning into the medical field, Dr. Parker pursued studies at Mayo Medical School and joined the U.S. Medical Corps, ultimately achieving the rank of captain. Specializing in emergency medicine, he served as director of emergency medicine at two hospitals and founded an emergency medicine contracting company to save a floundering hospital from closure. He now speaks out as an advocate for physicians and patients and embodies a rare blend of scientific expertise, military leadership, and medical acumen, contributing significantly to the advancement of space exploration and the betterment of human health and safety.

#physician #advocacy #moral #injury #pain #opioids #DOJ #DEA #crisis

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!